Global Assets Advisory LLC Takes Position in Hims & Hers Health, Inc. (NYSE:HIMS)

Global Assets Advisory LLC purchased a new stake in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 58,325 shares of the company's stock, valued at approximately $1,673,000.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Farallon Capital Management LLC grew its position in Hims & Hers Health by 64,338.5% during the fourth quarter. Farallon Capital Management LLC now owns 8,377,000 shares of the company's stock valued at $202,556,000 after purchasing an additional 8,364,000 shares in the last quarter. Arrowstreet Capital Limited Partnership boosted its stake in shares of Hims & Hers Health by 192.0% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 6,304,202 shares of the company's stock valued at $152,436,000 after buying an additional 4,145,305 shares during the period. Vanguard Group Inc. grew its holdings in shares of Hims & Hers Health by 11.1% during the 4th quarter. Vanguard Group Inc. now owns 20,257,116 shares of the company's stock valued at $489,817,000 after acquiring an additional 2,020,722 shares in the last quarter. Renaissance Technologies LLC grew its holdings in shares of Hims & Hers Health by 29.0% during the 4th quarter. Renaissance Technologies LLC now owns 6,951,152 shares of the company's stock valued at $168,079,000 after acquiring an additional 1,562,302 shares in the last quarter. Finally, Invesco Ltd. increased its stake in shares of Hims & Hers Health by 613.9% in the fourth quarter. Invesco Ltd. now owns 1,277,026 shares of the company's stock worth $30,878,000 after acquiring an additional 1,098,148 shares during the last quarter. Institutional investors and hedge funds own 63.52% of the company's stock.

Insider Activity at Hims & Hers Health

In related news, COO Melissa Baird sold 33,333 shares of the firm's stock in a transaction that occurred on Monday, April 21st. The stock was sold at an average price of $25.78, for a total transaction of $859,324.74. Following the completion of the transaction, the chief operating officer now owns 805,083 shares in the company, valued at $20,755,039.74. This trade represents a 3.98% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Oluyemi Okupe sold 23,107 shares of Hims & Hers Health stock in a transaction on Monday, June 23rd. The shares were sold at an average price of $47.25, for a total value of $1,091,805.75. Following the completion of the transaction, the chief financial officer now owns 63,222 shares of the company's stock, valued at approximately $2,987,239.50. The trade was a 26.77% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 706,454 shares of company stock worth $35,220,112. 13.71% of the stock is owned by corporate insiders.

Hims & Hers Health Stock Performance

Shares of Hims & Hers Health stock traded up $4.96 on Thursday, reaching $46.37. The stock had a trading volume of 64,151,410 shares, compared to its average volume of 22,812,861. The business's 50-day moving average price is $49.27 and its two-hundred day moving average price is $39.37. The stock has a market cap of $10.38 billion, a P/E ratio of 67.20, a price-to-earnings-growth ratio of 1.62 and a beta of 2.09. Hims & Hers Health, Inc. has a fifty-two week low of $13.47 and a fifty-two week high of $72.98.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its earnings results on Monday, May 5th. The company reported $0.20 EPS for the quarter, topping the consensus estimate of $0.12 by $0.08. Hims & Hers Health had a net margin of 9.24% and a return on equity of 22.75%. The firm had revenue of $586.01 million for the quarter, compared to the consensus estimate of $535.21 million. During the same quarter last year, the firm posted $0.05 EPS. The business's quarterly revenue was up 110.7% on a year-over-year basis. As a group, equities analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Analyst Ratings Changes

HIMS has been the subject of a number of research reports. Needham & Company LLC reissued a "hold" rating on shares of Hims & Hers Health in a research report on Monday. UBS Group set a $30.00 price target on Hims & Hers Health in a report on Monday. TD Cowen cut Hims & Hers Health from a "buy" rating to a "hold" rating and lowered their price target for the company from $44.00 to $30.00 in a research note on Tuesday, April 29th. Wall Street Zen upgraded Hims & Hers Health from a "hold" rating to a "buy" rating in a report on Sunday, June 15th. Finally, Piper Sandler reiterated a "neutral" rating and issued a $39.00 target price (up from $35.00) on shares of Hims & Hers Health in a research note on Tuesday, May 6th. Three analysts have rated the stock with a sell rating, nine have issued a hold rating and three have issued a buy rating to the company. According to MarketBeat, the company has a consensus rating of "Hold" and an average price target of $38.31.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.